The Action for Pulmonary Fibrosis Mike Bray Research Fellowship in Idiopathic Pulmonary Fibrosis is a £300,000 grant that will be awarded over three years to an outstanding research project, which enhances understanding of the causes of IPF or advances treatments. It is named after and in memory of the charity’s founder and former chairman, who passed away early last year.
Preliminary applications for the APF Mike Bray Research Fellowship are now closed and the selection process is nearing completion.
Idiopathic Pulmonary Fibrosis is a fatal lung disease with no known cause, no cure and limited treatments. More than 30,000 people in the U.K. suffer from IPF with 5,000 deaths every year, more than die from leukaemia. More than half of IPF patients die within 3-5 years of diagnosis.
The funding has been raised purely through the commitment and generosity of individual fundraisers and those who have made donations in memory of a loved one, often at a very difficult time in their own lives. Our supporters told us how important it was that the money they raised went towards research – we listened.
APF Trustee, Dr Helen Parfrey, Consultant Respiratory Physician at Papworth Hospital said:
“Mike was a patient of mine at Papworth Hospital following his diagnosis with pulmonary fibrosis in 2005. He received a single lung transplant five years later and, together with his wife, Elizabeth and a small group of patients, family members and clinicians, founded APF in 2013.
“ Mike sadly passed away in January this year after what he described as ‘six good years of extra life’, but not before witnessing the charity go from strength to strength.
“We have been astounded at the tremendous amount of support we have received during the four years since we began and are very proud to be able to contribute the very significant sum of £300,000 to a research project in Mike’s name.”
APF Trustee, Mrs Elizabeth Bray said:
“Mike would have been very proud to have a research project in his name. Being a patient and understanding so well the effects of IPF on the patient, their family and friends, after his transplant he worked hard to raise awareness and to encourage actions to improve the treatment and care for all IPF patients. This grant will help to achieve those improvements. Thank you to all who have made it possible.”